<DOC>
	<DOCNO>NCT00660257</DOCNO>
	<brief_summary>A single center , non-randomized clinical trial two-dose prim healthy adult evaluate safety immunogenicity booster dose inactivate pandemic influenza ( H5N1 ) vaccine ( whole-virion , aluminium-adjuvanted ) .</brief_summary>
	<brief_title>Safety Immunogenicity Booster Dose An Inactivated , Adjuvanted Whole-Virion Pandemic Influenza ( H5N1 ) Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Had receive twodose prim vaccination previous phase I trial Be able show legal identity card sake recruitment Be able understand sign inform consent . Womanï¼š Who breastfeed plan become pregnant study Any history allergic reaction vaccine egg Autoimmune disease immunodeficiency Diabetes mellitus ( type I II ) , exception gestational diabetes Serious angioedema episode within previous 3 year require medication previous two year Hypertension well control medication 145/95 mmHg enrollment Active malignancy treat malignancy reasonable assurance sustain cure malignancy likely recur period study GuillainBarre Syndrome Women subject positive urinary pregnancy test Any history immunosuppressive medication cytotoxic medication inhale corticosteroid within past six month History blood product administration within 3 month dose Administration investigational research agent within 30 day dose Administration live attenuate vaccine within 30 day dose Administration subunit inactivate vaccine , e.g . pneumococcal vaccine , allergy treatment antigen injection , within 14 day dose Be receive antiTB prophylaxis therapy currently Axillary temperature &gt; 37.0 centigrade time dose Psychiatric condition precludes compliance protocol ; past present psychosis ; past present bipolar disorder require therapy well control medication past two year ; disorder require lithium ; suicidal ideation occur within five year prior enrollment Any medical , psychiatric , social condition , occupational reason responsibility , judgment investigator , contraindication protocol participation impair volunteer 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>